Frequently Asked Questions
Aromasin belongs to the group of medicines known as aromatase inhibitors. Particularly in postmenopausal women, it interferes with an enzyme called aromatase, which is required to produce the female sex hormones, oestrogens. Treatment for hormone-dependent breast cancer involves lowering oestrogen levels in the body.
Adjuvant treatment of postmenopausal women
- Postmenopausal women with early breast cancer who test positive for the oestrogen receptor can switch to the medication aromasin after receiving two to three years of tamoxifen to finish a total of five years of adjuvant hormone therapy.
Advanced Breast Cancer in Postmenopausal Women
- Treats postmenopausal individuals with metastatic breast cancer whose condition worsened after receiving tamoxifen.
Precautions to special population
Pregnancy: The use of aromasin during pregnancy is not recommended as it could harm the fetus.
Breast-feeding: The use of aromasin is not recommended in lactating women.
Children: The use of aromasin is not recommended in children as it is not safe and effective.
Elderly: Aromasin is taken by elderly individuals based on the recommendation of the doctor. Before taking it, always seek advice from your doctor.